Celldex Therapeutics (CLDX) Posts Narrower than Expected Q2 Loss of 27c/Sh.
Tweet
Share
E-mail
Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $1.95 million versus the consensus estimate of $2.43 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Dave & Buster's Entertainment (PLAY) Misses Q2 EPS by 46c
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
